Company Profile

Relavo LLC
Profile last edited on: 5/19/2023      CAGE: 8HAG9      UEI: YLY4JGH9AAM7

Business Identifier: Device to prevent infection in peritoneal dialysis: form of at-home treatment for end-stage renal disease.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 West Pratt Street Suite 200
Baltimore, MD 21201
   (781) 820-3093
Location: Single
Congr. District: 07
County: Baltimore City

Public Profile

With the objective of making peritoneal dialysis (PD) safer for ESRD patients, the female-founded team of biomedical engineers from Johns Hopkins University structure their effort around making home dialysis more accessible - achieving that objective by minimizing the risk of infection with their developed technology: PeritoneX. Peritoneal dialysis (PD) is a form of treatment for kidney failure allowing patients to receive treatment daily at homes versus their spending 15-20 hours a week in a dialysis clinic. However, PD is under-utilized as a treatment due to the risk of infection: with only 10% of patients using PD. The problem is an infection of the peritoneal membrane commonly caused by bacteria entering the patientÂ’s body from touch or air contaminations of PD supplies during treatment setup - an affliction occuring in 30% of patients and requiring hospitalization in 50% of cases. The assembled team of Johns Hopkins students originally pitched their medical device for safe at-home dialysis at a university demo day and- successfully that day - drew in financial support. Subsequently - in 2020 - the young team also took a $500,000 KidneyX Prize and also has participated in various global accelerators.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NSF $1,255,750
Project Title: A Novel Disinfection Method to Prevent Infection in Peritoneal Dialysis

Key People / Management

  Sarah Lee -- CEO and Co-Founder

  Anna Bailey -- Chief Innovation Officer & Co-Founder

  Tejasvi Desai -- Chief Technology Officer & Co-Founder

Company News

There are no news available.